Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 58 min ago
Peer-reviewedCC BY-NC-NDTranslational lung cancer research

Beyond the blood-brain barrier: amivantamab plus lazertinib in EGFR-mutant non-small cell lung cancer with brain and leptomeningeal metastases.

  • Kelsey Pan1
  • Shi-Yong Sun1
  1. 1Winship Cancer Institute, Emory University, Atlanta, GA, USA.
Read full textPDFDOICite

Related

  1. Amivantamab and lazertinib in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer with brain and leptomeningeal metastases: an editorial on efficacy, challenges in assessment, and future directions.
    Vinay R Nittur, Yoojin Jo, Misako Nagasaka
    Translational lung cancer researchPeer-reviewedCC BY-NC-NDFull textOncologyEurope PMC
  2. Long-Term Impact of First-Line Amivantamab Plus Lazertinib Versus Osimertinib on Mechanisms of Acquired Resistance in MARIPOSA: A Brief Report
    Hidetoshi Hayashi, Byoung Chul Cho, David R. Spigel +19
    Journal of Thoracic OncologyPeer-reviewedCC BY5 citedOncologyHAL
  3. First-Line Lorlatinib for ALK-Rearranged Pulmonary Large-Cell Neuroendocrine Carcinoma with Brain Metastases and Suspected Leptomeningeal Involvement: A Case Report and Literature Review
    Yoshio Nakano, Kazuya Nishimura, Hiroka Serizawa +5
    Internal MedicinePeer-reviewedCC BY-NC-NDFull textGeneral medicineJ-STAGE
  4. Case Report: Prolonged survival following multimodal treatment of leptomeningeal metastases in triple-negative glycogen-rich clear cell breast carcinoma
    Yun-Chih Lo, Chun-Chieh Wu, Shang-Chun Hung +2
    Frontiers in OncologyPeer-reviewedCC BY 4.0Full textOncologyCrossrefPMC
  5. Incremental Value of Radiation Dose for Prognostic Stratification Beyond Performance Status in Palliative Radiation Therapy for Bone Metastases
    Advances in radiation oncologyPeer-reviewedCC BYFull textGeneral medicineEurope PMC

Cite

BibTeXRIS
BibTeX
@article{pan2026beyond,
  title = {{Beyond the blood-brain barrier: amivantamab plus lazertinib in EGFR-mutant non-small cell lung cancer with brain and leptomeningeal metastases.}},
  author = {Kelsey Pan and Shi-Yong Sun},
  journal = {Translational lung cancer research},
  year = {2026},
  month = oct,
  doi = {10.21037/tlcr-2026-1009},
  url = {https://europepmc.org/article/MED/42999429},
  note = {CC BY-NC-ND},
}
RIS
TY  - JOUR
TI  - Beyond the blood-brain barrier: amivantamab plus lazertinib in EGFR-mutant non-small cell lung cancer with brain and leptomeningeal metastases.
AU  - Kelsey Pan
AU  - Shi-Yong Sun
PY  - 2026
DA  - 2026/10/20
JO  - Translational lung cancer research
DO  - 10.21037/tlcr-2026-1009
UR  - https://europepmc.org/article/MED/42999429
SN  - 2218-6751
SN  - 2226-4477
ER  -